1.14
0.00%
0.00
アフターアワーズ:
1.15
0.01
+0.88%
前日終値:
$1.14
開ける:
$1.17
24時間の取引高:
419.30K
Relative Volume:
0.13
時価総額:
$150.49M
収益:
$3.25M
当期純損益:
$-116.80M
株価収益率:
-0.3738
EPS:
-3.05
ネットキャッシュフロー:
$-98.17M
1週間 パフォーマンス:
-3.39%
1か月 パフォーマンス:
-27.85%
6か月 パフォーマンス:
-63.69%
1年 パフォーマンス:
-95.39%
Rapt Therapeutics Inc Stock (RAPT) Company Profile
名前
Rapt Therapeutics Inc
セクター
電話
(650) 489-9000
住所
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
RAPT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
1.14 | 150.49M | 3.25M | -116.80M | -98.17M | -3.05 |
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-12-26 | アップグレード | H.C. Wainwright | Neutral → Buy |
2024-11-13 | ダウングレード | Stifel | Buy → Hold |
2024-11-11 | ダウングレード | JP Morgan | Neutral → Underweight |
2024-11-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
2024-05-14 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
2024-05-10 | ダウングレード | Barclays | Overweight → Equal Weight |
2024-05-10 | ダウングレード | Guggenheim | Buy → Neutral |
2024-02-22 | ダウングレード | UBS | Buy → Neutral |
2024-02-21 | ダウングレード | H.C. Wainwright | Buy → Neutral |
2024-02-21 | ダウングレード | JP Morgan | Overweight → Neutral |
2024-02-21 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-02-20 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
2024-02-16 | 開始されました | Evercore ISI | Outperform |
2024-02-15 | 開始されました | Wolfe Research | Outperform |
2023-09-14 | 開始されました | Berenberg | Buy |
2023-08-09 | 開始されました | Stifel | Buy |
2023-06-15 | 開始されました | Barclays | Overweight |
2023-01-04 | 開始されました | Guggenheim | Buy |
2022-12-01 | 開始されました | Goldman | Buy |
2022-09-21 | 開始されました | CapitalOne | Overweight |
2022-05-24 | 再開されました | Cantor Fitzgerald | Overweight |
2021-12-09 | 開始されました | JP Morgan | Overweight |
2021-08-12 | 開始されました | SVB Leerink | Outperform |
2021-06-21 | 開始されました | Piper Sandler | Overweight |
2020-06-01 | 開始されました | H.C. Wainwright | Buy |
2020-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
2020-04-13 | 開始されました | ROTH Capital | Buy |
2019-11-25 | 開始されました | BMO Capital Markets | Outperform |
2019-11-25 | 開始されました | UBS | Buy |
2019-11-25 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Rapt Therapeutics Inc (RAPT) 最新ニュース
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Recommendation of “Hold” by Brokerages - Defense World
Form 424B3 RAPT Therapeutics, Inc. - StreetInsider.com
SEC Form 424B3 filed by RAPT Therapeutics Inc. - Quantisnow
RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull - MSN
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Stake Boosted by Barclays PLC - Defense World
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Sold by Jane Street Group LLC - Defense World
RAPT Therapeutics Plans Phase 2b Trials for RPT904 - TipRanks
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Purchased by Barclays PLC - Defense World
RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
RAPT Therapeutics appoints new board chair By Investing.com - Investing.com Nigeria
RAPT Therapeutics appoints new board chair - Investing.com
RAPT Therapeutics, Inc. Announces Board Changes - Marketscreener.com
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors - The Manila Times
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors - Yahoo Finance
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $9.56 Average Target Price from Brokerages - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of “Hold” from Analysts - Defense World
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - News & Insights
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5% - MarketBeat
Notable analyst calls this week: FREYR Battery, Apple and ServiceNow among top picks - Seeking Alpha
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright - Yahoo Finance
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to Buy Rating - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT Therapeutics Shares Surge After HC Wainwright Upgrade - Marketscreener.com
HC Wainwright & Co. Upgrades RAPT Therapeutics (RAPT) - MSN
RAPT upgraded at H.C. Wainwright on China licensing deal - MSN
RAPT stock upgraded at H.C. Wainwright (RAPT:NASDAQ) - Seeking Alpha
RAPT Therapeutics (NASDAQ:RAPT) Upgraded by HC Wainwright to "Buy" Rating - MarketBeat
This Progressive Analyst Turns Bullish; Here Are Top 3 Upgrades For Thursday - Benzinga
RAPT Therapeutics Announces License Agreement and Private Placement - Defense World
RAPT Therapeutics and Shanghai Jemincare sign anti-IgE antibody agreement - Yahoo Finance
RAPT Therapeutics soars as it looks to raise $150M in private placement - MSN
RAPT Therapeutics sees 113% spike on allergy med licensing deal & private placement - Mugglehead
RAPT Therapeutics, Inc. announced that it expects to receive $149.976555 million in funding from a group of investors - Marketscreener.com
RAPT Therapeutics stock rises following licensing deal with Jemincare By Investing.com - Investing.com Nigeria
RAPT Therapeutics stock rises following licensing deal with Jemincare - Investing.com
Peninsula drugmaker lands $150 million, food allergy drug to fill pipeline holeSan Francisco Business Times - The Business Journals
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Yahoo Finance
US Stocks Mixed, Dow Tumbles 150 Points - Benzinga
Stock market today: iLearningEngines plunges by 60.44% while Reliance Global Group surged by 231.67% in early trading session - Business Upturn
RAPT Therapeutics secures rights to new allergy antibody - Investing.com
RAPT Therapeutics Partners with Jemincare and Secures Funding - TipRanks
RAPT Therapeutics prices 100M shares at 85c in private placement - TipRanks
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical - GlobeNewswire
RAPT Therapeutics Announces $150 Million Private Placement - GlobeNewswire
RAPT Therapeutics and Shanghai Jemincare Pharmaceutical Announce Exclusive License Agreement - The Bakersfield Californian
RAPT Therapeutics Secures $672.5M Deal for Breakthrough Anti-IgE Antibody with Extended Half-Life - StockTitan
Charles Schwab Investment Management Inc. Cuts Stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World
Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings? - MSN
RAPT Therapeutics stock plunges to 52-week low of $0.92 - Investing.com India
RAPT Therapeutics' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com
RAPT Therapeutics stock plunges to 52-week low of $0.92 By Investing.com - Investing.com Nigeria
Rapt Therapeutics Inc (RAPT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):